Advancing Regenerative Medicine™
Applied Biologics is a fully-integrated life sciences company providing research, product development, manufacturing and distribution of medical technologies. Since 2010, we’ve been dedicated to providing doctors innovative biologic solutions to deliver optimal patient outcomes.
XWRAP® Amniotic Membrane-derived Allograft
XWRAP® is a dehydrated amniotic membrane for use as a protective barrier and wound covering for acute and chronic wounds.
XWRAP® is intended for homologous use as a protective barrier or cover applied to partial and full thickness acute and chronic wounds such as diabetic, venous, arterial, pressure and other ulcers, as well as traumatic and complex wounds, burns, surgical and Mohs surgery sites.
XWRAP® is available in six specialized formulations, each engineered to address specific wound healing challenges and surgical requirements across diverse clinical applications.
Why Choose Applied Biologics?
Through innovation and development of new technologies with a proven track record of success and accelerating rate of growth, Applied Biologics is committed to being a leader in regenerative medicine products.
State-of-the-Art Facility
Our high-capacity GMP (Good Manufacturing Practice) facility in Scottsdale, Arizona represents the pinnacle of regenerative medicine manufacturing technology and capabilities.
Made in the USA
All products are exclusively manufactured domestically with no internationally sourced components, ensuring complete quality control and supply chain reliability.
Advanced Processing
Through scientific advancements in aseptic recovery and proprietary processing techniques, we maintain the highest standards of product quality and safety.
Highest Quality Standards
Our products are screened in a CLIA-certified laboratory that meets or exceeds American Association of Tissue Banks (AATB) criteria.
Research & Publications
Applied Biologics is committed to advancing the scientific understanding of amniotic membrane allografts through rigorous clinical investigation. We are currently sponsoring a multi-center randomized controlled clinical trial evaluating the efficacy of XWRAP® and standard of care versus standard of care alone in the management of nonhealing diabetic foot ulcers. This study represents our dedication to evidence-based medicine and our commitment to validating the clinical benefits of XWRAP® for patients and healthcare providers.
Official Title
Evaluating the Efficacy of XWRAP®, a Single Layer Placental-based Allograft, and Standard of Care Versus Standard of Care.
ClinicalTrials.gov ID
NCT06564831
Status
Recruiting
Study Start Date
September 2024
Trial completion
Fall 2026
Interim data
Recent Publications
“Evaluation of single layer amniotic membrane in the management of nonhealing diabetic foot ulcers: an interim analysis of CAMPX”
International Journal of Tissue Repair, vol. 1, no. 1, Oct. 2025, https://doi.org/10.63676/m04r0s60.
Partner With Applied Biologics
Whether you’re a healthcare provider looking to enhance patient outcomes with advanced wound care solutions or a clinical leader ready to advance the field through regenerative medicine research, we partner with independent practices and wound care centers nationwide to deliver proven products and comprehensive clinical support.